Local biotech company HLB is stepping up efforts to win a novel drug approval in the United States for its liver cancer treatment Rivoceranib, after completing a pre-new drug application (NDA) meeting with the U.S. Food and Drug Administration (FDA), the company said Wednesday. 

Please refer to the following website for further details: 

https://www.koreatimes.co.kr/www/nation/2022/10/779_337765.html?utm_source=na